Pooled analysis from eight clinical trials among women with HR+HER2- advanced breast cancer reported that CDKi combination therapy is associated with higher risks of all-grade and grade 3 and 4 (G3-4) toxicities, including neutropenia, leukopenia, anemia and non-hematologic events [14]. This evidence concerns the gene ERBB2 and Decreased total neutrophil count.